Week In Review
1.COVID-19 cases reached to 36.5 million world wide and 6.91 million in India.
2.Drug Controller General for India has rejected the request of Dr.Reddy's laboratories application for conducting the phase-III clinical trails of Sputnik-V. The regulator noted that safety and immunogenicity data from early studies being conducted overseas is small with no information regarding Indian participant.
3.Phase- III clinical trails of Indigenous COVID- 19 vaccine Covaxin, from Bharat Biotech will start with in two weeks after approval From DGCI.
4.United Arab Emirates company is near to end of phase- III clinical trails of Chinese COVID-19 vaccine.
5.Medtronic Pvt. Ltd. has announced the launch of Azure Pacemaker with Bluesync technology, First in India and only pacemaker that can directly communicate with smartphones and tablets.
6.Zydus Cadila announced launch of pressurized Metered Dose Inhaler for COPD patient.
7.Drug major Glenmark Pharma has received approval from USFDA for Dimethyl Fumarate delayed release capsules, used for treatment of relapsing multiple sclerosis in adults.
8.Oxford vaccine for COVID-19 can be roll out before 2021.
9.Abbott launches Duphalac bears in India, It encourages growth of good bacteria while reducing bad bacteria.
10.Drug Controller General for India has given permission to start Phase-1 human clinical trails for 'Antisera' that was developed by injecting inactivated SARS-COV-2 virus in horses.
11.I2Pure lunches I2Cure ,iodine based antiseptic lotion that provide full proof protection against COVID-19 and other bacteria and virus for 12 hours.
12.Nobel prize 2020 in chemistry is awarded to Emmanuelle Charpentier and Jennifer A. Dounda for development of CRISPR method for Genome editing.


It has great information about novel treatment for COPD patients
ReplyDeleteWell done
Keep it up....